Business growth

Roche announced FDA approval for Gavreto to treat non-small cell lung cancer with positive RET fusion. The drug received FDA approval based on ARROW Phase I / II study data. In the U.S., Gavreto will sell Roche's subsidiary Genentech and second developer of Blueprint Medicines. Outside of the Americas, with the exception of mainland China, Roche will commercialize the product itself.